Recent News

• 11.04.2026 - IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
• 11.03.2026 - IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
• 10.30.2026 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 10.23.2026 - IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
• 10.19.2026 - IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
• 09.28.2026 - IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
• 09.25.2026 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 09.09.2026 - IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
• 09.01.2026 - IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
• 08.31.2026 - IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

Recent Filings

• 11.03.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 11.03.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2026 - 8-K Current report
• 11.03.2026 - EX-99.1 EX-99.1
• 10.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.06.2026 - 144 Report of proposed sale of securities
• 08.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 8-K Current report
• 08.04.2026 - EX-99.1 EX-99.1